DOI: 10.36347/sjmcr.2023.v11i04.078

Pages: 733-734

Inflammatory bowel diseases (IBD) include Crohn's disease and ulcerative colitis. IBD represents a pathology that evolves through relapses interspersed with remission. Anemia is the most common extra-intestinal complication in inflammatory bowel disease (IBD). Depending on the hemoglobin level, the anemia is mild, moderate or severe. It can affect quality of life and increase the hospitalization rate of patients. The reported prevalence of anemia in patients with IBD ranges from 6% to 74%. Although the causes of anemia in IBD are multifactorial, iron deficiency anemia remains the most common. Management is based on treating the disease and correcting the anemia with injectable iron. The aim of the work is to take stock of the prevalence and treatment of chronic anemia during IBD, as well as the impact of the covid19 period on the monitoring of this chronic pathology in our structure.